Siga Technologies, Inc. Declares Special Cash Dividend, Payable on April 23, 2026 Mar 27
SIGA Technologies, Inc. to Report Fiscal Year 2025 Results on Mar 10, 2026 Mar 03
SIGA Technologies, Inc. to Report Q3, 2025 Results on Nov 06, 2025 Oct 30
SIGA Technologies, Inc. to Report Q2, 2025 Results on Aug 05, 2025 Jul 29
SIGA Technologies, Inc. to Report Q1, 2025 Results on May 08, 2025 May 01
SIGA Technologies, Inc., Annual General Meeting, Jun 10, 2025 Apr 21
SIGA Technologies, Inc. Declares Special Cash Dividend, Payable on May 15, 2025 Apr 08
SIGA Technologies, Inc. Announces Retirement of John M. Keane from Its Board of Directors Mar 18
SIGA Technologies, Inc. to Report Q4, 2024 Results on Mar 11, 2025 Mar 04
SIGA Technologies Announces TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses Jan 02
The National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) Announces Interim Results from STOMP Study of SIGA’s Tecovirimat Dec 11
SIGA Technologies, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 31
SIGA Technologies, Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jul 25
First quarter 2024 earnings released: EPS: US$0.14 (vs US$0.013 loss in 1Q 2023) May 09
New minor risk - Share price stability May 09
Investor sentiment improves as stock rises 15% May 03
SIGA Technologies, Inc. to Report Q1, 2024 Results on May 07, 2024 May 03
SIGA Technologies, Inc., Annual General Meeting, Jun 11, 2024 Apr 28
New major risk - Revenue and earnings growth Apr 24
Investor sentiment improves as stock rises 17% Apr 04
Investor sentiment improves as stock rises 63% Mar 19
Upcoming dividend of US$0.60 per share Mar 18
Full year 2023 earnings: EPS and revenues miss analyst expectations Mar 14
Siga Technologies, Inc. Declares A Special Cash Dividend, Payable on April 11, 2024 Mar 12
SIGA Technologies, Inc. to Report Q4, 2023 Results on Mar 12, 2024 Mar 06
High number of new directors Feb 02
New major risk - Revenue and earnings growth Jan 24
Third quarter 2023 earnings released: US$0.006 loss per share (vs US$0.45 profit in 3Q 2022) Nov 09
SIGA Technologies, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 27
SIGA Technologies, Inc. Appoints Jay K. Varma as EVP and Chief Medical Officer Sep 07
Second quarter 2023 earnings released: US$0.04 loss per share (vs US$0.028 profit in 2Q 2022) Aug 09
SIGA Technologies, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Jul 29
Inaugural dividend of US$0.45 per share May 08
First quarter 2023 earnings released: US$0.013 loss per share (vs US$0.005 loss in 1Q 2022) May 06
SIGA Technologies, Inc. Declares a Special Cash Dividend, Payable on June 1, 2023 May 05
Investor sentiment deteriorates as stock falls 18% Mar 09
Full year 2022 earnings: EPS and revenues miss analyst expectations Mar 03
SIGA Technologies Announces Planned Retirement of CEO Phil Gomez in 2023 Jan 18
Investor sentiment improved over the past week Jan 16
High number of new directors Dec 02
SIGA Technologies, Inc. Announces Directorate Appointments Nov 16
Third quarter 2022 earnings released: EPS: US$0.45 (vs US$0.042 loss in 3Q 2021) Nov 04
SIGA Technologies, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 28
SIGA Technologies, Inc. Provides Update on Progress in Clinical Trials to Assess Use of Tpoxx ® (Tecovirimat) for Treatment of Monkeypox Oct 13
Investor sentiment deteriorated over the past week Sep 19
Investor sentiment deteriorated over the past week Aug 24
Now 21% undervalued Aug 18
James Antal Provides Notice to SIGA Technologies, Inc. of His Resignation from the Board of Directors Aug 06
Second quarter 2022 earnings released: EPS: US$0.028 (vs US$0.002 in 2Q 2021) Aug 05
SIGA Technologies, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 29
Investor sentiment improved over the past week Jul 15
SIGA Technologies Receives Approval from UK for Tecovirimat Jul 09
Investor sentiment improved over the past week Jun 24
Independent Director exercised options and sold US$70k worth of stock Jun 17
Investor sentiment improved over the past week Jun 02
SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat) May 20
Investor sentiment improved over the past week May 19
First quarter 2022 earnings: EPS exceeds analyst expectations May 06
SIGA Technologies, Inc. Declares a Special Dividend of the Company, Payable on June 2, 2022 May 06
High number of new directors Apr 27
SIGA Technologies, Inc., Annual General Meeting, Jun 14, 2022 Apr 15
Full year 2021 earnings: EPS exceeds analyst expectations Mar 06
SIGA Technologies, Inc. Announces Start of Tpoxx® Post-Exposure Prophylactic Clinical Trials Mar 04
SIGA Technologies, Inc Receives Approval from the European Medicines Agency for Tecovirimat Jan 12
Independent Director recently sold US$235k worth of stock Dec 11